IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study
NCT07596888
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Purpose: To assess the safety and tolerability of a single dose of IAP086 in persons with HIV suppressed on stable ART Participants: 30 people from UNC within 18 to 70years of age. People with HIV on ART with plasma HIV-1 RNA < 50 copies/mL for 12 months prior to screening. Procedures (methods): The participant's standard of care ART regimen is continued throughout the study period. This study requires an overnight stay in a research unit.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV-1-infection
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- University of North Carolina, Chapel Hill
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
North Carolina · 2
- University of North Carolina · Chapel Hill, NC
- Duke Early Phase Clinical Research Unit · Durham, NC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.